Several predictive biomarkers have been proposed for anti-VEGF therapies; however, no validated biomarkers for cancer treatment exist. For patients with glioblastoma, who have a dismal prognosis, ...

A biomarker has been identified that may help to identify patients with recurrent glioblastoma who stand to respond better to anti-VEGF endothelial growth factor therapy with cediranib. In a phase-2 ...

The immunosuppressive and hypoxic tumor microenvironment (TME) remains a major obstacle to impede cancer immunotherapy. Here, we showed that elevated levels of Delta-like 1 (DLL1) in the breast and ...

Pharmacogenetic approach for capecitabine or 5-fluorouracil (5FU) selection to be combined with oxaliplatin as first-line chemotherapy in advanced colorectal cancer No significant financial ...

TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced today the first subjects have been dosed in a Phase 1 study of AV-001 in healthy subjects.

TORONTO--(BUSINESS WIRE)--Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with ...

Vascular functions of PlGF remain poorly understood and controversial. Here, we show that tumor cell-derived PIGF-1 and PIGF-2 displayed significant remodeling effects on the tumor vasculature, ...

Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial Treatment of glioblastoma (GBM), the most common primary ...

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor ...

Restoring order to the chaotic blood vessels inside a tumor opens a window of opportunity for attacking it. Surprisingly, drugs meant to destroy vasculature can make the repairs and may help reverse ...